- Home
- HOWL vs FBRX Comparison
HOWL vs FBRX Comparison
Compare HOWL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- FBRX
- Stock Information
- Founded
- HOWL 2017
- FBRX N/A
- Country
- HOWL United States
- FBRX United States
- Employees
- HOWL N/A
- FBRX N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- FBRX Health Care
- Exchange
- HOWL Nasdaq
- FBRX Nasdaq
- Market Cap
- HOWL 37.9M
- FBRX 35.3M
- IPO Year
- HOWL 2021
- FBRX N/A
- Fundamental
- Price
- HOWL $0.87
- FBRX $6.23
- Analyst Decision
- HOWL Strong Buy
- FBRX Strong Buy
- Analyst Count
- HOWL 3
- FBRX 3
- Target Price
- HOWL $9.00
- FBRX $80.50
- AVG Volume (30 Days)
- HOWL 232.7K
- FBRX 27.8K
- Earning Date
- HOWL 05-08-2025
- FBRX 05-20-2025
- Dividend Yield
- HOWL N/A
- FBRX N/A
- EPS Growth
- HOWL N/A
- FBRX N/A
- EPS
- HOWL N/A
- FBRX N/A
- Revenue
- HOWL $1,143,000.00
- FBRX N/A
- Revenue This Year
- HOWL N/A
- FBRX N/A
- Revenue Next Year
- HOWL $733.33
- FBRX N/A
- P/E Ratio
- HOWL N/A
- FBRX N/A
- Revenue Growth
- HOWL N/A
- FBRX N/A
- 52 Week Low
- HOWL $0.60
- FBRX $4.11
- 52 Week High
- HOWL $6.34
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- HOWL 46.85
- FBRX 43.67
- Support Level
- HOWL $0.80
- FBRX $6.13
- Resistance Level
- HOWL $0.97
- FBRX $7.70
- Average True Range (ATR)
- HOWL 0.07
- FBRX 0.81
- MACD
- HOWL 0.02
- FBRX -0.01
- Stochastic Oscillator
- HOWL 41.92
- FBRX 47.50
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).